Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs

NCT05223413 is registered in ClinicalTrials.gov with Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III as lead sponsor.

NCT NCT05223413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05223413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs
Lead sponsor
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Phase
Not applicable
Overall status
Recruiting
Start date
January 18, 2022
Completion date
December 31, 2026
Enrollment
608 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

anthracycline-induced cardiac toxicity, lymphoma